Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Scientific Capacity Inadequate; New Device Technology At Risk

This article was originally published in The Gray Sheet

Executive Summary

CDRH is not equipped to understand the science behind many cutting-edge device technologies, says a Nov. 29 report from the Subcommittee on Science and Technology, an ad hoc panel of the FDA Science Board

You may also be interested in...



Hamburg’s Departure Hinged On Selection Of FDA Leadership Team

Medical countermeasures expert Luciana Borio moves to chief scientist role; Hamburg offers preview of the leadership approaches of Stephen Ostroff and Robert Califf.

Science Board Investigates How FDA Has Responded To Critical 2007 Report

A subcommittee is evaluating progress the agency has made in regulatory science since the 2007 report, “FDA Science and Mission at Risk,” was issued, while identifying future needs.

Regulatory News In Brief

GAO reports on transparency of federal agencies. FDA Science Board to meet in February. More regulatory news.

Related Content

UsernamePublicRestriction

Register

MT025569

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel